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Abstract 
Bisphenol-A (BPA), a chemical -xenoestrogen- used in the production of the plastic lining of food 
and beverage containers, is present in the urine of almost the entire population. Recent studies 
have shown that BPA exposure is associated with podocytopathy, increased urinary albumin 
excretion (UAE), and hypertension. Since these changes are characteristic of early diabetic 
nephropathy (DN), we explored the renal effects of BPA and diabetes including the potential 
role of sexual dimorphism. Male and female mice were included in the following animals' 
groups: control mice (C), mice treated with 21.2 mg/Kg of BPA in the drinking water (BPA), 
diabetic mice induced by streptozotocin (D), and D mice treated with BPA (D+BPA). Male mice 
form the D+BPA group died by the tenth week of the study due probably to hydro-electrolytic 
disturbances.  
Although BPA treated mice did not show an increase in serum creatinine, as observed in D and 
D+BPA groups, they displayed similar alteration to those of the D group, including increased in 
kidney damage biomarkers NGAL and KIM-1, UAE, hypertension, podocytopenia, apoptosis, 
collapsed glomeruli, as well as TGF-β, CHOP and PCNA upregulation. UAE, collapsed glomeruli, 
PCNA staining, TGF-β, NGAL and animal survival, significantly impaired in D+BPA animals. 
Moreover, UAE, collapsed glomeruli and animal survival also displayed a sexual dimorphism 
pattern. 
In conclusion, oral administration of BPA is capable of promoting in the kidney alterations that 
resemble early DN. Further translational studies are needed to clarify the potential role of BPA 
in renal diseases, particularly in diabetic patients. 
Keywords: Bisphenol A, mouse, diabetes, diabetic nephropathy. 
 
Highlights 
- Oral administration of BPA at a concentration below the "no observed adverse effect level" 
(NOAEL) promotes in the mice alterations that resemble early diabetic nephropathy. 
-Mice receiving BPA develop proteinuria, hypertension, podocytopenia, apoptosis, collapsed 
glomeruli, as well as the upregulation of kidney damage biomarkers NGAL and KIM-1, and the 
TGF-β system. 
- Proteinuria, collapsed glomeruli, and animal survival displayed a sexual dimorphism pattern in 
diabetic mice receiving BPA. 
 
1. Introduction 
Diabetes mellitus (DM) is a growing disease that affects an increasing number of people. In 1980 
it affected 108 million people globally [1], increasing to 171 million in 2000 [2]. Interestingly, in 
2014, the number of patients augmented to 422 million [1]. According to studies conducted by 
the International Diabetes Federation, it is estimated that almost 500 million people in the world 
are currently living with diabetes. That number is projected to reach 578 million in 2030 and 700 
million in 2045 [3]. Of all of them, it is estimated that about half of patients with type 1 diabetes 
develop diabetic nephropathy (DN) throughout their lives, being 30-50% in the case of patients 
with type 2 diabetes [4]. 
In the same way, an increase in the prevalence of diabetic kidney disease has also been 
observed. Gheith et al. [4] determined an increase from 7.1% (1988-1994) to 10.7% (2005-2008) 
in people over 65 years of age. DN is also the most common cause of end-stage renal disease, 
having been observed in the United States to cause up to 80% of cases [5]. DN has been 
recognized as a worldwide medical catastrophe and is now the most important etiology of end-
stage renal failure in developed countries [6]. However, since not all diabetic patients suffer 
renal alterations, it is considered that there must be numerous environmental and biological 
factors yet to be determined. 
Parallel to the increase in chronic diseases, an increase in exposure to xenobiotic compounds, 
such as bisphenol A (BPA), has been observed [7,8]. BPA is an essential element in manufacturing 
PVC and epoxy resins, used in numerous sectors such as the food industry, medical-surgical 
material, thermal paper cash register receipts, or even clothes [9–12]. In this way, BPA levels 
have been detected in the vast majority of foods, which manifests as significant levels of BPA in 
almost the entire human population studied, reaching percentages of 95% in the United States 
[13], 97% in Spain [14], 90-100% in China [15,16] or even 100% in Canada [17]. 
BPA is known to act as an endocrine disruptor, and due to its physical properties, it is capable of 
crossing any physiological barrier, such as the blood-brain or placental barrier [18]. In the last 
20 years, various studies have determined that BPA can affect numerous organs and systems, 
such as the female and male reproductive system, the cardiovascular system and the endocrine 
system, or even the correct fetal development, to name a few examples [19–22]. In this sense, 
a pattern of sexual dimorphism has been observed during the gestational or perinatal period, 
compared to the same exposure to BPA, reaching differences on hepatic [23,24], adipogenic 
[25], neurological [26–28], endocrine [29], immunological [30], and renal development [31]. 
Pollock et al. [32] determined that the kidney is one of the organs where more BPA can be 
quantified, and this concentration rises before prolonged exposure over time, which also 
suggests the existence of a possible accumulation. 
Epidemiological studies in humans suggest the possible association between high urinary BPA 
levels and predisposition to albuminuria [33,34] or hypertension [35,36]. Moreover, Olea et al. 
[37] in an experimental animal model have shown the development of podocytopathy and 
increased urinary albumin excretion (UAE) in mice after five weeks of i.p. exposure of BPA. 
Furthermore, BPA exposure has been associated with hypertension in mice [22]. 
Since these changes are characteristic of early DN, herein we explored the hypothesis that oral 
BPA exposure, being the most important one in mammals, might resemble DN and promote the 
progression of kidney damage. Moreover, we also studied well-characterized molecules 
involved in the pathophysiology of DN, such as the proapoptotic and profibrogenic TGF-β, and 
the well-known inflammatory mediators MCP-1 and TNF-α. 
 
2. Material and methods 
2.1. Animal model. CD1 mice (25–30 g) were used in all the experiments. All the studies were 
performed following guidelines established by Institutional Animal Care and Use Committees at 
the University of Alcalá. Mice were housed in a temperature‐controlled room (21 ± 2°C) on a 
14/10 h light/dark cycle under pathogen‐free conditions and food ad libitum. Mice were given 
free access to water or BPA-containing water at a dose of 150 μg/ml (Sigma, Saint Louis, MO). 
Four different animal groups were studied: Control (C), non-diabetic animals with BPA in the 
drinking water (BPA) 150 µg/ml, (21.2 mg/kg/day), diabetic animals without BPA (D), and 
diabetic animals with BPA in the drinking water (D+BPA).  
In total forty non-diabetic mice were used, 20 mice as control and 20 mice treated with BPA. 
Diabetes was induced by three daily consecutive intraperitoneal injections of streptozotocin 
(STZ) (Sigma), 65 mg/kg body weight in citrate buffer, pH 4.5 (vehicle) [38]. Mice with blood 
glucose >300 mg/dL were included in the study (n=45). Male and female mice were used in 
approximately equal number with the exception of the male D+BPA group (17 male and 8 
female) due to the mortality of the former group at 10 weeks. For this reason, the period of the 
study was limited to eight weeks using 5 to 7 animals per group except for the Kaplan-Mayer 
survival table.  
Mice were placed in metabolic cages, and 24‐h urine was collected for biochemical 
measurement as previously reported [39]. After eight weeks of treatment and development of 
the diabetic model, the animals were sacrificed under isoflurane. Blood was taken by cardiac 
puncture under ether anesthesia for biochemical measurements. The right kidney of each 
animal was removed, weighed, frozen in liquid nitrogen, and stored at −80 °C for subsequent 
total RNA extraction. The left kidney was weighed and fixed in 10% buffered formaldehyde for 
morphological and immunohistochemistry studies. The degree of renal hypertrophy was 
expressed as an index, the ratio of kidney weight to total body weight. 
2.2. Determination of biochemical test. Quantifications of plasma sodium, potassium, albumin, 
creatinine, and urine albumin and creatinine were performed with an ADVIA Chemistry system 
(Siemens Healthineers). 
2.3. Immunohistochemistry. Serial sections (4 µm thicknesses) from mice kidneys formalin-fixed 
and embedded in paraffin were deparaffinized with xylene, rehydrated, and placed in 10 mM 
sodium citrate buffer, pH 6.0, and heated in a conventional pressure cooker for 2 min. The 
sections were allowed to cool for 20 min. After rinsing with distilled water, the sections were 
washed twice in Tris buffer saline (TBS), pH 7.6, for 5 min. Endogenous peroxidase activity was 
inhibited by incubation with 3% H2O2 for 20 min. Sections were subsequently washed with 
distilled H2O and TBS and incubated with 3% normal donkey serum plus 0.05% Triton X-100 in 
TBS (blocking solution) at room temperature for 30 min to prevent nonspecific binding of the 
first antibody. Afterward, sections were incubated overnight at 4°C with primary antibodies 
diluted in blocking solution, which was diluted 1:9 in TBS. (WT-1, 1:1000; CHOP, 1:300; PCNA, 
1:1500; MCP-1, 1:400; 4-Hydroxynonenal (4-HNE) 1:250). Then, the sections were washed and 
incubated in primary antibodies amplifier Quanto (Ultravision Quanto detection system–
peroxidase, Master Diagnóstica, Granada, Spain) for 10 min. After an extensive wash in TBS, the 
sections were incubated in polymer Quanto for 10 min. The peroxidase activity was detected 
using the DAB kit (Master Diagnóstica). Tissue sections were counterstained with hematoxylin, 
dehydrated, cleared in xylene, and mounted in Entellan®. 
The immunoreactivity of each focus of interest was measured using the stereological software 
Motic Images Advanced 3.2 (Motic China Group Co, Ltd). This program allows the selection of 
fields to be studied by systematic random sampling after the input of an appropriate sampling 
fraction. An average of 10 light microscopic fields per section was scanned using the x20 
objective. The staining intensity was measured using a grey level scale (0: white; 255: black) with 
a negative image. All results are expressed as mean ± SEM. 
2.4. TUNEL assay. For the detection of apoptotic cells, the DeadEndTM Fluorometric TUNEL 
System was applied (Promega, Madison, WI, USA) to paraffin-embedded sections according to 
the manufacturer's instructions. Then, the sections were incubated with an anti-FITC-HRP for 30 
min. and the reaction product in nuclei was developed with DAB. 
2.5. Total RNA extraction and quantitative RT-PCR. Total RNA was isolated from each mouse 
kidney homogenate obtained using TriReagent (Sigma-Aldrich). Total RNA was quantified by 
Nanodrop 1000 Spectrophotometer (Thermo Scientific). A total of 500 g of RNA was reverse 
transcribed into cDNA using the High Capacity cDNA Promega Kit according to the 
manufacturer's instructions (5 minutes 65°C and 1 hour 37°C). PCR was performed duplicated 
for each sample using an adequate dilution of cDNA as a template for different genes (see 
supplementary material Table S1 for SYBR Green primers and TaqMan probes). β-actin and 36B4 
were used as housekeeping genes. The amplification was carried out in an ABI PRISM 7000 
Sequence Detection System (Applied Biosystems) by using the following conditions: 2 minutes 
50°C, 10 minutes 95°C, 40 cycles (15 seconds 95°C, 1 minute 60°C). Reagents were from Applied 
Biosystems (for TaqMan probes) and SYBR Green (for SYBR Green primers). We used a standard 
curve method, using the untreated samples as a calibrator, to calculate the relative quantity of 
gene expression. We used the BestKeeper software tool (http://www.gene-quantification.info/) 
to validate housekeeping genes [40]. 
2.6. Measurement of blood pressure (tail cuff method). We used a non-invasive pressure gauge 
(LE 5001 Pressure Meter; Letica Scientific Instruments, Hospitalet, Spain) to measure the blood 
pressure. The measurements were always made at the same time of day, with the least possible 
stress for the animal (acoustic and luminous). Being nocturnal animals and having a high 
inactivity peak at 8 a.m., they were not manipulated until at least two hours later. The animals 
were prewarmed to 30°C with a heater (LE5660/6, Letica Scientific Instruments). The 
sphygmomanometer and the pulse transducer were never placed in the area near the animal's 
body because they can cause damage. 
2.7. Statistical analysis. All results were expressed as mean ± SEM. p < 0.05 was considered 
statistically significant. To determine the effects of treatments, one-way ANOVA or Kruskal-
Wallis followed by a Bonferroni or Dunns test, respectively, were carried out. To determine sex 
differences in the BPA and diabetes treatment, two-way ANOVA followed by a Tukey's multiple 
comparisons test or Sidak's multiple comparisons test were carried out. The p-values presented 
in figures and tables corresponded to post hoc test. All statistical analyses were performed using 
the GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, CA, USA). 
 
3. Results 
3.1. Animals display a sexual survival dimorphism pattern. As shown in figure 1A, the Kaplan-
Meier animal survival analysis showed that all-male D+BPA mice died by the tenth week of 
treatment while no animal loses were found among the other experimental animal groups. In 
order to obtain all the biological samples needed to complete the animal’s studies, some male 
animals were included in the studied groups as described in the methods section.   
Besides dehydration, no other potential cause of death was observed in the bodies of dead mice. 
As shown in figure 1B, both D and D+BPA groups showed a significant increase in urinary output 
than the control littermates. However, only D group showed significant differences between 
males and females. As expected, these animal groups display an increased value of plasma 
sodium together with a decreased potassium (figures 1C and 1D), albeit these values did not 
display a sexual dimorphism pattern. Unfortunately, one limitation of the study is the lack of 
biochemical data beyond the study's eight weeks. Therefore, although the cause of the male 
D+BPA group's death cannot be determined with certainty, we can only assume that it was 
related to hydroelectrolytic disturbances. 
 
3.2. Animal body weight and renal functional parameters. As previously described [41–44], 
control male mice showed a significant increase in body weight and renal hypertrophy compared 
to females ´littermates (figures 1E and 1F). As shown in figure 1E, compared to control mice, the 
average animal body weight was not affected in the BPA group, while both D and D+BPA groups 
showed a significant decrease in this parameter. Moreover, both control male and D male mice 
showed a significant increase in body weight compared to females' littermates. The D and 
D+BPA mice showed a significant increase in the renal hypertrophy index compared to the 
control group. Of note is that the females of the D+BPA group develop an increase in this 
parameter similar to males. In the rest of the groups, the females showed a lower hypertrophy 
index than their male littermates (figure 1F). 
At 8 weeks of treatment, the glycemia of diabetic animals remained above 400 mg/dl in all 
animals, while BPA group were not significantly different from those of the C group (figure 2A). 
As expected, all animal groups studied display a significant increase in UAE compared to the C 
group (figure 2B). UAE was significantly higher in the D group compared to the BPA group. 
Interestingly, male D+BPA mice display a significant increase in UAE compared to the BPA group, 
demonstrating a sexual dimorphism pattern compared to their female littermates.  
Moreover, a significant decrease in plasma albumin was observed in D and D+BPA (figure 2C). 
Although endogenous creatinine clearance not showed significant differences among animal 
groups studied, plasma creatinine displayed a statistically significant increase in both D and 
D+BPA groups compared to their correspondent's controls (figure 2D and 2E). To further 
investigate BPA effects at the molecular level on the kidney, the gene expression of the kidney 
damage biomarkers Havcr-1 and Lidocalpin-2, which codify NGAL and KIM-1, respectively, were 
evaluated [45,46] (figure 2F and 2G). Both mRNAs were significantly increased in all treated mice 
in comparison to their control littermates. Interestingly, NGAL also showed a significant further 
increase in diabetic animals receiving BPA. Thus, kidney damage biomarkers supported the 
notion that BPA exposures to mice induced kidney damage in non-diabetic mice and 
exacerbated injury in diabetic mice. No sexual dimorphism was observed in these parameters. 
As shown in figure 2H and 2I, systolic and diastolic arterial blood pressures were substantially 

















Figure 1. Survival, plasma ions, and physiological study. A. Kaplan-Meier survival graph. Note that the 
survival of all groups is 100%, except for the D+BPA group. For this reason, all symbols and lines overlap 
at the same height, preventing correct viewing. B. Body weight, in grams. Diabetic animals showed a 
significant decrease in body weight than C and BPA groups. Note that only C and D groups showed sexual 
dimorphism. C. Renal hypertrophy index (kidney weight [mg] / animal weight [g] * 1000). All diabetic 
animals showed a significant increase in renal hypertrophy index. Note that C, BPA, and D groups showed 
sexual dimorphism. D. 24-hour diuresis, in ml. All diabetic animals excreted volumes of urine between 5 
and 10 times higher than control and BPA groups. E. Plasma sodium, in mmol/l. All diabetic animals 
showed elevated plasma sodium concentrations. F. Plasma potassium, in mmol/l. Only the D+BPA group 
showed low plasma potassium concentrations. All groups with different letters have significant 
differences (p<0.01). Letter c represents significant differences with diabetic female (p<0.0001). *p<0.05; 
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A B C 
D E F 
**p<0.01 comparing to their respective control group. $p<0.05; $$p<0.01; $$$p<0.001 comparing 
between males and females of the same group. The graph represents mean values ± SEM. One-way 
ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way ANOVA test 






















Figure 2. Biochemical study of the kidney and arterial pressure. A. Blood glucose. All diabetic animals 
showed higher blood glucose at the end of the experiment (8 weeks). B. Albuminuria, expressed in mg of 
albumin excreted in 24 hours. Note that all groups showed elevated levels of albuminuria compared with 
the control group. C. Plasma albumin, in g/dl. All diabetic animals showed low values of plasma albumin, 
in the nephrotic range. D. Plasma creatinine, in mg/dl. All diabetic animals showed high plasma creatinine 
values. E. Creatinine clearance. All groups showed similar creatinine clearance values. F. NGAL qPCR. G. 
KIM-1 qPCR. H. After eight weeks of treatment, all groups showed a significant increase in systolic pressure 
than the control group. I. Diastolic pressure showed the same pattern than systolic pressure. $p<0.05 
comparing between males and females of the same group. All groups with different letters have 
significant differences (p<0.05). Letter c represents significant differences with BPA group (p<0.05). The 
graph represents mean values ± SEM. One-way ANOVA or Kruskal-Wallis test was performed for the 
comparison between groups. A two-way ANOVA test was performed for the comparison between sexes. 
3.3. Histological, immunohistochemical, and Q-PCR studies. BPA and D groups display similar 
renal histological changes at both glomerular and tubular compartments, including collapsed 
glomeruli, tubular dilatation, sloughing off the tubuloepithelial cells, and hyaline casts in the 
tubules' lumen.  Diabetic mice treated with BPA showed similar histological alterations observed 
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in these groups. Of note, glomerular damage analyzed as collapsed corpuscles percentage 
showed a sexual dimorphism pattern in BPA and D+BPA groups being male mice significantly 


























Figure 3. Histological examination (PAS-Alcian blue staining). A. Control kidney. B. Mice BPA-treated 
showed altered renal corpuscles and dilated convoluted tubules. C. The kidney of the diabetic mice 
showed both Bowman’s capsules and convoluted tubules extremely dilated. D. D+BPA mice showed 
mesangial expansion, some corpuscles were destroyed (*), and the epithelium in some tubules was 
damaged (star) (X300). E. Histogram compares the corpuscular surface in each group observing 
statistically significant differences between females and males in both control and BPA-treated groups. F. 
Histogram represents the collapsed renal corpuscles percentage, showing a sexual dimorphism pattern in 
BPA and D+BPA groups. *p<0.05; **p<0.01 using one-way ANOVA or Kruskal-Wallis test for the 
comparison between groups. A two-way ANOVA test was performed for the comparison between sexes. 
$$p<0.01 comparing between males and females of the same group. 
Immunolabeling with WT-1, a specific marker of podocytes, demonstrated that podocytes cell 
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littermates (figure 4). Interestingly, D+BPA animals display a further decrease in this parameter 






















Figure 4. WT-1 immunostaining. A. Control kidney. B. Mice BPA-treated is showing a reduction in the 
podocytes number vs. control animal. C. Diabetic mice presented a higher podocyte number than BPA-
treated animals but lower than control. D. D+BPA mice had the lowest number of podocytes (X300). E. 
The histogram shows statistically significant differences between all experimental groups. All groups with 
different letters have significant differences (p<0.01). One-way ANOVA or Kruskal-Wallis test was 
performed for the comparison between groups. A two-way ANOVA test was performed for the 
comparison between sexes. 
Cell death, including apoptosis, as analyzed by CHOP immunohistochemistry and TUNEL assay, 
respectively, were significantly increased in all group studies in comparison to their control 
littermates. D group presented the highest optical density in CHOP immunostaining (figure 5). 






































































Figure 5. CHOP immunostaining. A. In the control group, the CHOP labeling was observed in the blood 
vessel endothelial cells. B. In BPA-treated kidneys, the immunolabeling was increased and appeared in 
the apical cytoplasm of the tubuloepithelial cells. C. Diabetic mice presented the highest immunoreaction 
to CHOP antibody. D. D+BPA mice presented elevated immunostaining but lower than in diabetic mice 
(X300). E. Histogram showing the optical density of CHOP immunostaining. All groups with different 
letters have significant differences (p<0.01). One-way ANOVA or Kruskal-Wallis test was performed for 


































































Figure 6. TUNEL assay. A. Kidneys from control the group presented a small number of apoptotic cells. B. 
BPA-treated mice presented a higher number of apoptotic cells than controls. C. In diabetic mice, kidneys 
from males had a high number of dead cells; however, the female mice were similar to the control group. 
D. D+BPA mice showed the highest number of apoptotic cells (X300). E. Histogram shows the gender 
differences in each group. $$$$ p<0.0001 females vs. males. All groups with different letters have 
significant differences (p<0.05). One-way ANOVA or Kruskal-Wallis test was performed for the comparison 
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To explore if there was a compensatory mitotic response to the observed increase in cell death, 
cell proliferation was analyzed by PCNA immunostaining. Both BPA and D groups develop a 
significant proliferative response, even higher in female mice than their male littermates (figure 
7). Interestingly, D+BPA group also showed PCNA-upregulation compared to their control 



























Figure 7. PCNA immunostaining. A. Control groups showed a low number of proliferating cells. B. Kidneys 
from BPA-treated mice presented a higher number of PCNA positive cells than control groups, especially 
females. C. Diabetic mice showed a number similar to control in males and higher in females. D. D+BPA 
mice presented a high number of proliferating cells without any difference between gender (X300). E. 
Histogram representing the gender differences in each group. All groups with different letters have 
significant differences (p<0.05). $p<0.05; $$$$p<0.0001 females vs. males.  One-way ANOVA or Kruskal-
Wallis test was performed for the comparison between groups. A two-way ANOVA test was performed 
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We then explored the potential role of oxidative stress as an inflammatory mediator by 
analyzing lipid peroxidation as 4-HNE staining (figure 8). Control and BPA animals showed a 
sexual dimorphism pattern being significantly higher in the male. All treated mice, except D+BPA 
























Figure 8. 4-HNE immunolabeling.  A. Control group. B. BPA-mice showed an important 4-HNE elevation, 
compared to their control group. Furthermore, BPA was the only treated group with sexual dimorphism 
pattern, similar than control. C. D group showed an important elevation without sexual dimorphism 
pattern. D. Only females D+BPA showed higher 4-HNE staining. E. Histogram represents the optical 
density of 4-HNE immunostaining. All groups with different letters have significant differences (p<0.01). 
One-way ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way 
ANOVA test was performed for the comparison between sexes. 
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We finally explored the potential role of several inflammatory mediators in the present 
experimental model (figures 9 and 10). No significant changes in the expression of TNF-α, MCP-
1, and IL-1β were observed in BPA-treated groups (figures 9A, B, C). The same expression pattern 
was observed in MCP-1 immunolabeling (figure 10). By contrast, all of them were significantly 
upregulated in D animal group. Moreover, D+BPA group showed a significant upregulation of 
MCP-1. Figure 9D showed a significant upregulation of IL-10 restricted to BPA animal group. TGF-
β and its receptor, a well-characterized system involved in both BPA and renal diabetic damage, 
were analyzed by Q-PCR. TGF-β was significantly upregulated in all animal groups, being 
significantly higher in the D+BPA group. The latter observation suggests that BPA might 
potentiate TGF-β upregulation in diabetic mice (figure 9E). Interestingly, the D+BPA group also 
displays the upregulation of the TGF-β receptor (figure 9F). No sexual dimorphisms were 
















Figure 9. Quantitative RT-PCR. A. TNF-α. The highest relative expression of the inflammatory messenger 
corresponds to the D group. B. MCP-1. As in the previous case, the highest relative expression of the 
inflammatory marker MCP-1 corresponds to the D group. C. IL-1β. The same expression pattern was 
observed as in the other two pro-inflammatory cytokines. D. IL-10. The expression of this anti-
inflammatory cytokine only increased in the BPA group E. TGF-β1. D+BPA group showed the highest 
relative expression of TGF-β1 mRNA. F.  TIIR. The only differences are observed between groups D and 
D+BPA. *p<0.05; **p<0.01 using the Kruskal-Wallis test for the comparison between groups. All groups 
with different letters have significant differences (p<0.05). Letter c represents significant differences with 
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Figure 10. MCP-1 immunolabeling. A. In control kidneys, MCP-1 was observed in the cytoplasm of some 
epithelial cells of the collecting tubules. B. In the BPA group, the labeling was similar to the control group. 
C. Diabetic mice showed a high number of labeled cells and higher intensity in the MCP-1 expression. D. 
Kidneys from D+BPA mice presented an elevated immunolabeling to MCP-1 antibody but with less 
intensity than diabetic animals (X300). E. Histogram represents the optical density of MCP-1 
immunostaining. All groups with different letters have significant differences (p<0.0001). One-way 
ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way ANOVA test 

































Experimental and human studies have demonstrated a significant association between urinary 
excretion of BPA and albuminuria, a well-known factor involved in the mechanism of renal 
disease progression [33,34,47,48]. In this regard, Hu et al. [47], in a prospective study of 302 
patients followed for six years, have demonstrated serum BPA as a predictor of chronic kidney 
disease in primary hypertension. Serum BPA was also described as a risk factor in the 
progression of diabetic nephropathy in patients with type 2 diabetes [48]. Our present study 
provides an experimental animal model to support these findings since we describe that the oral 
administration of BPA is capable of promoting in the kidney pathophysiological and molecular 
alterations that resemble early DN, such as increased in UAE, hypertension, podocytopenia, 
apoptosis, collapsed glomeruli as well as CHOP and TGF-β system upregulation. 
We presently used the STZ model, which is considered the ‘work horse’ for experimental studies 
in diabetic nephropathy [49,50]. Consistent with previous findings in this model, diabetic mice 
developed renal hypertrophy and an increase in UAE, hypertension, podocytopenia, apoptosis 
[39,51–55], and the upregulation of CHOP, PCNA, MCP-1, and TGF-β throughout this study 
[51,52]. 
Regarding BPA doses used in our study’s, animals received 150 µg/ml (21.2 mg/kg). Currently, it 
is accepted that the "no observed adverse effect level", known as NOAEL, in the renal system is 
50 mg/kg [56,57], which is at least twice times higher than the dose used. European Food Safety 
Authority (EFSA) currently uses this NOAEL dose to estimate the tolerable daily intake (TDI) of 4 
µg/kg in humans [57–59]. In the EFSA 2015 report, it is estimated that the total exposure to BPA 
in the population could reach almost half of the TDI (around 1.5 µg/kg) [57], which is consistent 
with using an equivalent concentration half of the NOAEL in animal models. 
BPA-treated mice did not display significant polyuria as expected from previous publish [37] and 
unpublished observations using BPA concentration higher than renal NOAEL. Therefore, polyuria 
and the risk of higher BPA exposure were restricted to D+BPA mice. In any case, the BPA group 
developed similar renal changes to those of the diabetic group. Although this represents a 
limitation in our studies, it emphasizes the role of BPA exposure and the importance of 
maintaining strict metabolic control of diabetic patients to avoid osmotic diuresis and BPA 
overexposure. 
One unexpected finding of this study was that all male mice from the D+BPA group died by the 
tenth week of the experimental procedure. Unfortunately, a limitation of the study is the lack of 
data beyond eight weeks. Therefore, albeit the cause of the death cannot be determined with 
certainty, we can only assume that it was related to hydroelectrolytic disturbances in animals 
with impaired renal function. 
In accordance with previous works [41–44], control male mice showed increased in body weight 
and renal hypertrophy compared to female littermates. Besides the observed sexual survival 
dimorphism pattern, other significant pathophysiological differences between male and female 
animals were found. Treated male animals display significant increases UAE, and renal damage 
analyzed as collapsed glomeruli. Renal cell proliferation, as analyzed by PCNA staining, was the 
only parameter found to be significantly higher in female animals than in the males' littermates.  
Although endogenous creatinine clearance showed no significant differences among animal 
groups studied, serum creatinine displayed a statistically significant increase in both D and 
D+BPA groups compared to their correspondent's controls. It is known that to a variable degree, 
tubules secrete creatinine, which, by itself, would lead to an overestimation of renal function 
[60]. To further investigate BPA effects at the molecular level on the kidney, the gene expression 
of the kidney damage biomarkers Havcr-1 and Lidocalpin-2, which codify KIM-1 and NGAL, 
respectively, were evaluated [45,46]. Both genes were significantly increased in all treated mice 
in comparison to their control littermates. Interestingly, NGAL also showed a significant further 
increase in diabetic animals receiving BPA. All renal functional data studied supported the notion 
that BPA exposures to mice induced kidney damage in control mice and exacerbated injury in 
diabetic mice. 
All treated male and female mice showed similar impairment of renal function. In contrast, male 
mice displayed a significant increase in urinary output restricted to D animal group, and female 
mice showed a significant increase in cell proliferation in this animal group. It is thus tempering 
to speculate, albeit not probed in the present setting, that increased urinary output could 
predispose to hydro electrolyte disturbances while increased in renal cell proliferation could, at 
least in theory, partially explain differences in sexual survival dimorphism pattern. On the other 
hand, D+BPA animal group did not display an additional effect on cell proliferation. 
Several studies have demonstrated that most renal cells grown in high glucose conditions 
initially present a self-limited proliferation, followed by cell cycle arrest in the G1-phase, 
undergoing cellular hypertrophy [51,61]. These cellular events require the combined effect of 
mitogen-induced entry into the cell cycle and subsequent arrest at the G1 modulated by cell 
cycle regulatory proteins, including TGF-β1. Therefore, it is possible to speculate that the intense 
hypertrophy response observed in the D+BPA group may abrogate the mitogenic effect induced 
by BPA. 
Sexual dimorphism could be due to different susceptibility to BPA, physiological differences, 
including sexual hormones, particularly androgen [62], or a combination of both. Indeed, 
different responses in males and females to the same exposure to BPA have been found. Most 
of the studies have been carried out mainly on the gestational or perinatal effect, where it has 
been determined that BPA can exert a different effect in males and females at the hepatic 
[23,24], adipogenic [25], neurological [26–28], endocrine [29], immunological [30], or renal level 
[31]. Furthermore, it has been observed that BPA is capable of inducing an agonist action on the 
estrogen receptor and an antagonist on the androgen receptor [63]. 
On the other hand, there is evidence that suggests that females have higher nephroprotection 
than males. In experimental animal models, female rats have increased protection against post-
ischemic renal failure [64], doxorubicin treatment [65], and cisplatin treatment [66]. 
Epidemiological studies in humans also suggest the existence of nephroprotection in women. In 
this sense, one of the most extensive studies carried out is that of Neugarten et al. [67], where 
after performing a meta-analysis with 68 different studies and a total of 11,345 patients, they 
determined that men with chronic kidney disease caused by various etiologies show a much 
faster decline in kidney function than women. In another epidemiological study with 27,805 
patients with type I diabetes, a statistically significant relationship was observed between the 
male sex and microalbuminuria development, an early marker of kidney disease [68]. 
Furthermore, probably because a BPA dose equivalent to half the NOAEL was used, the BPA 
group results do not show remarkable differences to the control group at the biometric and 
biochemical levels. However, an increase in albuminuria (less than in the diabetic groups, but 
equally significant) and a significant increase in blood pressure were observed. On the other 
hand, the histological studies showed interesting differences to the control group by showing 
the collapsed glomeruli, and a reduction in the number of cells, with the subsequent 
confirmation by TUNEL of the increase of apoptotic cells and a reduction in the number of 
podocytes labeled with WT-1.  
Regarding sexual dimorphism, were observed differences in the renal hypertrophy index and 
albuminuria, with males presenting a higher number in both parameters. Although podocyte 
(WT-1) immunostaining showed no sexual dimorphism, particularly in the D+BPA group, the 
number collapsing glomerulus did show sexual dimorphism. Thus, damaged glomeruli could 
account for the observed increase in the UAE in the male D+BPA group.   
 
 
In general, the results show that the route of administration of BPA and the dose used after 
eight weeks of treatment can exert an effect on the renal system similar to that described in the 
early stages of the development of diabetic nephropathy [69,70] at a dose lower than that 
considered "NOAEL" of the renal system [56].  
Although there are limitations when using mouse models for assessing renal failure or long-term 
histomorphological changes [71], our findings may have pathophysiological implications since 
the amount of proteinuria, podocyte number and the upregulation of kidney damage 
biomarkers are reliable predictors of the progression of renal disease [37,72–75]. Together with 
our present findings, all the available data strongly suggest that even low-grade proteinuria 
associated with BPA exposure might involve podocyte damage of an uncertain (or as yet 
unexplored) outcome, jointly with the biomarkers mentioned above are indicators of the need 
for future studies and raising a red flag of caution against increasing BPA exposure. Our data 
agree with Ruiz-Priego et al. [76], supporting the use of NGAL and KIM-1 as biomarkers of BPA-
nephropathy. 
Animals treated with BPA showed a significant increase in the expression of the CHOP protein. 
The kidney is one of the organs with the highest ER stress susceptibility because the fractional 
protein synthesis rates are almost half the total body load daily [77]. The possibility that ER stress 
is involved in the development of diabetic nephropathy has been described. Among the three 
signaling pathways that make up the ER stress response system, two of them are protective, and 
the remaining one, ERK-ATF4-CHOP, induces apoptosis in some kidney diseases [78]. It is 
interesting to note that both diabetic animals (as in other publications [79]) and those treated 
with BPA showed high CHOP levels. In this way, the hypothesis that BPA can induce similar 
damage to diabetic nephropathy is reaffirmed. 
In order to get inside into the molecular mechanisms involves in the renal changes observed, we 
first analyzed the proapoptotic and profibrogenic TGF-β system. As expected, diabetic and BPA 
groups display the upregulation of TGF-β, a cytokine involved in hypertrophy, apoptosis, and 
renal fibrosis. Interestingly, this upregulation was significantly higher in the D+BPA group, thus 
suggesting a molecular mechanism for the observed renal parameters impairment in the latter 
group. 
We then analyzed the renal expression of MCP-1, TNF-α and IL-1 well-known pro-inflammatory 
mediators in DN [80]. As expected, these molecules were found to be upregulated in D mice. On 
the contrary, BPA mice did not show changes in the expression of these pro-inflammatory 
mediators. It is well stablished that BPA can promote an inflammatory response by upregulating 
inflammatory mediators such as IL-1β, TNF-α, or MCP-1 [76,81,82], it is also known that it can 
also trigger the expression of anti-inflammatory molecules like IL-10 or TGF-β [83,84]. Herein we 
observed a significant upregulation of IL-10 restricted to BPA-treated mice. This finding could 
account, at least in part, for the lack of activation of proinflammatory mediators in this animal 
group.  
In any case, recent observations using a BPA concentration higher than renal NOAEL, 
demonstrate the upregulation of several proinflammatory mediators (including MCP-1, RANTES 
or IL-6) [76]. All data available strongly suggest that the level of BPA exposure might be critical 
to promote renal inflammation. 
In conclusion, we observed that oral administration of BPA is capable of promoting in the kidney 
alterations that resemble early DN, such as increased in kidney damage biomarkers NGAL and 
KIM-1, UAE, hypertension, podocytopenia, apoptosis, collapsed glomeruli as well as TGF-β, 
CHOP and PCNA upregulation, albeit they did not develop changes in serum creatinine as 
observed in D mice. Moreover, UAE, collapsed glomeruli, PCNA staining, TGF-β (TIIR), and animal 
survival, significantly impaired in diabetic animals receiving BPA. Furthermore, UAE, collapsed 
glomeruli and animal survival also displayed a sexual dimorphism pattern. 
Collectively, these data show that further translational studies are needed to clarify the potential 
role of BPA in renal diseases, particularly in diabetic patients.  
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Supplementary Table 1. SYBR Green primers and TaqMan probes. 
RT-PCR primers   
TNF-α Forward 5´- AGGCACTCCCCCAAAAGATG-3´ 
 Reverse 5´-TGAGGGTCTGGGCCATAGAA 
TGF-β1 Forward 5´-GCAACATGTGGAACTCTACCAG-3’ 
 Reverse 5´-CAGCCACTCAGGCGTATCA-3’ 
TIIR Forward     5′- CCTACTCTGTCTGTGGATGACCT - 3′  
 Reverse 5´- ACTTCCGGGGCCATGTAT - 3′ 
MCP-1 Forward  5’- CACTCACTCCACAACCCAAGA - 3’ 
 Reverse  5’- CAAAGACCCTCAAAACATCCC - 3’ 
IL-10 Forward  5′- AGGGTGTCTCCTTCCTCACA - 3’ 
 Reverse  5′- TGTTACACTCGCCCCCTTTG - 3’ 
IL-1β Forward  5′- TGGGCCTCAAAGGAAAGAAT - 3’ 
 Reverse  5′- CAGGCTTGTGCTCTGCTTGT - 3’ 
KIM-1 Forward  5′- ATGAATCAGATTCAAGTCTTC - 3’ 
 Reverse  5′- TCTGGTTTGTGAGTCCATGTG - 3’ 
NGAL Forward  5′- CACCACGGACTACAACCAGTTCGC - 3’ 
 Reverse  5′- TCAGTTGTCAATGCATTGGTCGGTG - 3’ 
TaqMan probes   
β-Actin Forward 5´- GCTCTGGCTCCTAGCACCAT- 3´ 
 Reverse 5´- GCCACCGATCCACACAGAGT- 3´ 
 Probe  5´- ATCAAGATCATTGCTCCTCCTGAGCGC- 3´ 
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Abstract 
Bisphenol-A (BPA), a chemical -xenoestrogen- used in the production of the plastic lining of food 
and beverage containers, is present in the urine of almost the entire population. Recent studies 
have shown that BPA exposure is associated with podocytopathy, increased urinary albumin 
excretion (UAE), and hypertension. Since these changes are characteristic of early diabetic 
nephropathy (DN), we explored the renal effects of BPA and diabetes including the potential 
role of sexual dimorphism. Male and female mice were included in the following animals' 
groups: control mice (C), mice treated with 21.2 mg/Kg of BPA in the drinking water (BPA), 
diabetic mice induced by streptozotocin (D), and D mice treated with BPA (D+BPA). Male mice 
form the D+BPA group died by the tenth week of the study due probably to hydro-electrolytic 
disturbances.  
Although BPA treated mice did not show an increase in serum creatinine, as observed in D and 
D+BPA groups, they displayed similar alteration to those of the D group, including increased in 
kidney damage biomarkers NGAL and KIM-1, UAE, hypertension, podocytopenia, apoptosis, 
collapsed glomeruli, as well as TGF-β, CHOP and PCNA upregulation. UAE, collapsed glomeruli, 
PCNA staining, TGF-β, NGAL and animal survival, significantly impaired in D+BPA animals. 
Moreover, UAE, collapsed glomeruli and animal survival also displayed a sexual dimorphism 
pattern. 
In conclusion, oral administration of BPA is capable of promoting in the kidney alterations that 
resemble early DN. Further translational studies are needed to clarify the potential role of BPA 
in renal diseases, particularly in diabetic patients. 
Keywords: Bisphenol A, mouse, diabetes, diabetic nephropathy. 
 
Highlights 
- Oral administration of BPA at a concentration below the "no observed adverse effect level" 
(NOAEL) promotes in the mice alterations that resemble early diabetic nephropathy. 
-Mice receiving BPA develop proteinuria, hypertension, podocytopenia, apoptosis, collapsed 
glomeruli, as well as the upregulation of kidney damage biomarkers NGAL and KIM-1, and the 
TGF-β system. 
- Proteinuria, collapsed glomeruli, and animal survival displayed a sexual dimorphism pattern in 
diabetic mice receiving BPA. 
 
1. Introduction 
Diabetes mellitus (DM) is a growing disease that affects an increasing number of people. In 1980 
it affected 108 million people globally [1], increasing to 171 million in 2000 [2]. Interestingly, in 
2014, the number of patients augmented to 422 million [1]. According to studies conducted by 
the International Diabetes Federation, it is estimated that almost 500 million people in the world 
are currently living with diabetes. That number is projected to reach 578 million in 2030 and 700 
million in 2045 [3]. Of all of them, it is estimated that about half of patients with type 1 diabetes 
develop diabetic nephropathy (DN) throughout their lives, being 30-50% in the case of patients 
with type 2 diabetes [4]. 
In the same way, an increase in the prevalence of diabetic kidney disease has also been 
observed. Gheith et al. [4] determined an increase from 7.1% (1988-1994) to 10.7% (2005-2008) 
in people over 65 years of age. DN is also the most common cause of end-stage renal disease, 
having been observed in the United States to cause up to 80% of cases [5]. DN has been 
recognized as a worldwide medical catastrophe and is now the most important etiology of end-
stage renal failure in developed countries [6]. However, since not all diabetic patients suffer 
renal alterations, it is considered that there must be numerous environmental and biological 
factors yet to be determined. 
Parallel to the increase in chronic diseases, an increase in exposure to xenobiotic compounds, 
such as bisphenol A (BPA), has been observed [7,8]. BPA is an essential element in manufacturing 
PVC and epoxy resins, used in numerous sectors such as the food industry, medical-surgical 
material, thermal paper cash register receipts, or even clothes [9–12]. In this way, BPA levels 
have been detected in the vast majority of foods, which manifests as significant levels of BPA in 
almost the entire human population studied, reaching percentages of 95% in the United States 
[13], 97% in Spain [14], 90-100% in China [15,16] or even 100% in Canada [17]. 
BPA is known to act as an endocrine disruptor, and due to its physical properties, it is capable of 
crossing any physiological barrier, such as the blood-brain or placental barrier [18]. In the last 
20 years, various studies have determined that BPA can affect numerous organs and systems, 
such as the female and male reproductive system, the cardiovascular system and the endocrine 
system, or even the correct fetal development, to name a few examples [19–22]. In this sense, 
a pattern of sexual dimorphism has been observed during the gestational or perinatal period, 
compared to the same exposure to BPA, reaching differences on hepatic [23,24], adipogenic 
[25], neurological [26–28], endocrine [29], immunological [30], and renal development [31]. 
Pollock et al. [32] determined that the kidney is one of the organs where more BPA can be 
quantified, and this concentration rises before prolonged exposure over time, which also 
suggests the existence of a possible accumulation. 
Epidemiological studies in humans suggest the possible association between high urinary BPA 
levels and predisposition to albuminuria [33,34] or hypertension [35,36]. Moreover, Olea et al. 
[37] in an experimental animal model have shown the development of podocytopathy and 
increased urinary albumin excretion (UAE) in mice after five weeks of i.p. exposure of BPA. 
Furthermore, BPA exposure has been associated with hypertension in mice [22]. 
Since these changes are characteristic of early DN, herein we explored the hypothesis that oral 
BPA exposure, being the most important one in mammals, might resemble DN and promote the 
progression of kidney damage. Moreover, we also studied well-characterized molecules 
involved in the pathophysiology of DN, such as the proapoptotic and profibrogenic TGF-β, and 
the well-known inflammatory mediators MCP-1 and TNF-α. 
 
2. Material and methods 
2.1. Animal model. CD1 mice (25–30 g) were used in all the experiments. All the studies were 
performed following guidelines established by Institutional Animal Care and Use Committees at 
the University of Alcalá. Mice were housed in a temperature‐controlled room (21 ± 2°C) on a 
14/10 h light/dark cycle under pathogen‐free conditions and food ad libitum. Mice were given 
free access to water or BPA-containing water at a dose of 150 μg/ml (Sigma, Saint Louis, MO). 
Four different animal groups were studied: Control (C), non-diabetic animals with BPA in the 
drinking water (BPA) 150 µg/ml, (21.2 mg/kg/day), diabetic animals without BPA (D), and 
diabetic animals with BPA in the drinking water (D+BPA).  
In total forty non-diabetic mice were used, 20 mice as control and 20 mice treated with BPA. 
Diabetes was induced by three daily consecutive intraperitoneal injections of streptozotocin 
(STZ) (Sigma), 65 mg/kg body weight in citrate buffer, pH 4.5 (vehicle) [38]. Mice with blood 
glucose >300 mg/dL were included in the study (n=45). Male and female mice were used in 
approximately equal number with the exception of the male D+BPA group (17 male and 8 
female) due to the mortality of the former group at 10 weeks. For this reason, the period of the 
study was limited to eight weeks using 5 to 7 animals per group except for the Kaplan-Mayer 
survival table.  
Mice were placed in metabolic cages, and 24‐h urine was collected for biochemical 
measurement as previously reported [39]. After eight weeks of treatment and development of 
the diabetic model, the animals were sacrificed under isoflurane. Blood was taken by cardiac 
puncture under ether anesthesia for biochemical measurements. The right kidney of each 
animal was removed, weighed, frozen in liquid nitrogen, and stored at −80 °C for subsequent 
total RNA extraction. The left kidney was weighed and fixed in 10% buffered formaldehyde for 
morphological and immunohistochemistry studies. The degree of renal hypertrophy was 
expressed as an index, the ratio of kidney weight to total body weight. 
2.2. Determination of biochemical test. Quantifications of plasma sodium, potassium, albumin, 
creatinine, and urine albumin and creatinine were performed with an ADVIA Chemistry system 
(Siemens Healthineers). 
2.3. Immunohistochemistry. Serial sections (4 µm thicknesses) from mice kidneys formalin-fixed 
and embedded in paraffin were deparaffinized with xylene, rehydrated, and placed in 10 mM 
sodium citrate buffer, pH 6.0, and heated in a conventional pressure cooker for 2 min. The 
sections were allowed to cool for 20 min. After rinsing with distilled water, the sections were 
washed twice in Tris buffer saline (TBS), pH 7.6, for 5 min. Endogenous peroxidase activity was 
inhibited by incubation with 3% H2O2 for 20 min. Sections were subsequently washed with 
distilled H2O and TBS and incubated with 3% normal donkey serum plus 0.05% Triton X-100 in 
TBS (blocking solution) at room temperature for 30 min to prevent nonspecific binding of the 
first antibody. Afterward, sections were incubated overnight at 4°C with primary antibodies 
diluted in blocking solution, which was diluted 1:9 in TBS. (WT-1, 1:1000; CHOP, 1:300; PCNA, 
1:1500; MCP-1, 1:400; 4-Hydroxynonenal (4-HNE) 1:250). Then, the sections were washed and 
incubated in primary antibodies amplifier Quanto (Ultravision Quanto detection system–
peroxidase, Master Diagnóstica, Granada, Spain) for 10 min. After an extensive wash in TBS, the 
sections were incubated in polymer Quanto for 10 min. The peroxidase activity was detected 
using the DAB kit (Master Diagnóstica). Tissue sections were counterstained with hematoxylin, 
dehydrated, cleared in xylene, and mounted in Entellan®. 
The immunoreactivity of each focus of interest was measured using the stereological software 
Motic Images Advanced 3.2 (Motic China Group Co, Ltd). This program allows the selection of 
fields to be studied by systematic random sampling after the input of an appropriate sampling 
fraction. An average of 10 light microscopic fields per section was scanned using the x20 
objective. The staining intensity was measured using a grey level scale (0: white; 255: black) with 
a negative image. All results are expressed as mean ± SEM. 
2.4. TUNEL assay. For the detection of apoptotic cells, the DeadEndTM Fluorometric TUNEL 
System was applied (Promega, Madison, WI, USA) to paraffin-embedded sections according to 
the manufacturer's instructions. Then, the sections were incubated with an anti-FITC-HRP for 30 
min. and the reaction product in nuclei was developed with DAB. 
2.5. Total RNA extraction and quantitative RT-PCR. Total RNA was isolated from each mouse 
kidney homogenate obtained using TriReagent (Sigma-Aldrich). Total RNA was quantified by 
Nanodrop 1000 Spectrophotometer (Thermo Scientific). A total of 500 g of RNA was reverse 
transcribed into cDNA using the High Capacity cDNA Promega Kit according to the 
manufacturer's instructions (5 minutes 65°C and 1 hour 37°C). PCR was performed duplicated 
for each sample using an adequate dilution of cDNA as a template for different genes (see 
supplementary material Table S1 for SYBR Green primers and TaqMan probes). β-actin and 36B4 
were used as housekeeping genes. The amplification was carried out in an ABI PRISM 7000 
Sequence Detection System (Applied Biosystems) by using the following conditions: 2 minutes 
50°C, 10 minutes 95°C, 40 cycles (15 seconds 95°C, 1 minute 60°C). Reagents were from Applied 
Biosystems (for TaqMan probes) and SYBR Green (for SYBR Green primers). We used a standard 
curve method, using the untreated samples as a calibrator, to calculate the relative quantity of 
gene expression. We used the BestKeeper software tool (http://www.gene-quantification.info/) 
to validate housekeeping genes [40]. 
2.6. Measurement of blood pressure (tail cuff method). We used a non-invasive pressure gauge 
(LE 5001 Pressure Meter; Letica Scientific Instruments, Hospitalet, Spain) to measure the blood 
pressure. The measurements were always made at the same time of day, with the least possible 
stress for the animal (acoustic and luminous). Being nocturnal animals and having a high 
inactivity peak at 8 a.m., they were not manipulated until at least two hours later. The animals 
were prewarmed to 30°C with a heater (LE5660/6, Letica Scientific Instruments). The 
sphygmomanometer and the pulse transducer were never placed in the area near the animal's 
body because they can cause damage. 
2.7. Statistical analysis. All results were expressed as mean ± SEM. p < 0.05 was considered 
statistically significant. To determine the effects of treatments, one-way ANOVA or Kruskal-
Wallis followed by a Bonferroni or Dunns test, respectively, were carried out. To determine sex 
differences in the BPA and diabetes treatment, two-way ANOVA followed by a Tukey's multiple 
comparisons test or Sidak's multiple comparisons test were carried out. The p-values presented 
in figures and tables corresponded to post hoc test. All statistical analyses were performed using 
the GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, CA, USA). 
 
3. Results 
3.1. Animals display a sexual survival dimorphism pattern. As shown in figure 1A, the Kaplan-
Meier animal survival analysis showed that all-male D+BPA mice died by the tenth week of 
treatment while no animal loses were found among the other experimental animal groups. In 
order to obtain all the biological samples needed to complete the animal’s studies, some male 
animals were included in the studied groups as described in the methods section.   
Besides dehydration, no other potential cause of death was observed in the bodies of dead mice. 
As shown in figure 1B, both D and D+BPA groups showed a significant increase in urinary output 
than the control littermates. However, only D group showed significant differences between 
males and females. As expected, these animal groups display an increased value of plasma 
sodium together with a decreased potassium (figures 1C and 1D), albeit these values did not 
display a sexual dimorphism pattern. Unfortunately, one limitation of the study is the lack of 
biochemical data beyond the study's eight weeks. Therefore, although the cause of the male 
D+BPA group's death cannot be determined with certainty, we can only assume that it was 
related to hydroelectrolytic disturbances. 
 
3.2. Animal body weight and renal functional parameters. As previously described [41–44], 
control male mice showed a significant increase in body weight and renal hypertrophy compared 
to females ´littermates (figures 1E and 1F). As shown in figure 1E, compared to control mice, the 
average animal body weight was not affected in the BPA group, while both D and D+BPA groups 
showed a significant decrease in this parameter. Moreover, both control male and D male mice 
showed a significant increase in body weight compared to females' littermates. The D and 
D+BPA mice showed a significant increase in the renal hypertrophy index compared to the 
control group. Of note is that the females of the D+BPA group develop an increase in this 
parameter similar to males. In the rest of the groups, the females showed a lower hypertrophy 
index than their male littermates (figure 1F). 
At 8 weeks of treatment, the glycemia of diabetic animals remained above 400 mg/dl in all 
animals, while BPA group were not significantly different from those of the C group (figure 2A). 
As expected, all animal groups studied display a significant increase in UAE compared to the C 
group (figure 2B). UAE was significantly higher in the D group compared to the BPA group. 
Interestingly, male D+BPA mice display a significant increase in UAE compared to the BPA group, 
demonstrating a sexual dimorphism pattern compared to their female littermates.  
Moreover, a significant decrease in plasma albumin was observed in D and D+BPA (figure 2C). 
Although endogenous creatinine clearance not showed significant differences among animal 
groups studied, plasma creatinine displayed a statistically significant increase in both D and 
D+BPA groups compared to their correspondent's controls (figure 2D and 2E). To further 
investigate BPA effects at the molecular level on the kidney, the gene expression of the kidney 
damage biomarkers Havcr-1 and Lidocalpin-2, which codify NGAL and KIM-1, respectively, were 
evaluated [45,46] (figure 2F and 2G). Both mRNAs were significantly increased in all treated mice 
in comparison to their control littermates. Interestingly, NGAL also showed a significant further 
increase in diabetic animals receiving BPA. Thus, kidney damage biomarkers supported the 
notion that BPA exposures to mice induced kidney damage in non-diabetic mice and 
exacerbated injury in diabetic mice. No sexual dimorphism was observed in these parameters. 
As shown in figure 2H and 2I, systolic and diastolic arterial blood pressures were substantially 

















Figure 1. Survival, plasma ions, and physiological study. A. Kaplan-Meier survival graph. Note that the 
survival of all groups is 100%, except for the D+BPA group. For this reason, all symbols and lines overlap 
at the same height, preventing correct viewing. B. Body weight, in grams. Diabetic animals showed a 
significant decrease in body weight than C and BPA groups. Note that only C and D groups showed sexual 
dimorphism. C. Renal hypertrophy index (kidney weight [mg] / animal weight [g] * 1000). All diabetic 
animals showed a significant increase in renal hypertrophy index. Note that C, BPA, and D groups showed 
sexual dimorphism. D. 24-hour diuresis, in ml. All diabetic animals excreted volumes of urine between 5 
and 10 times higher than control and BPA groups. E. Plasma sodium, in mmol/l. All diabetic animals 
showed elevated plasma sodium concentrations. F. Plasma potassium, in mmol/l. Only the D+BPA group 
showed low plasma potassium concentrations. All groups with different letters have significant 
differences (p<0.01). Letter c represents significant differences with diabetic female (p<0.0001). *p<0.05; 
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**p<0.01 comparing to their respective control group. $p<0.05; $$p<0.01; $$$p<0.001 comparing 
between males and females of the same group. The graph represents mean values ± SEM. One-way 
ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way ANOVA test 






















Figure 2. Biochemical study of the kidney and arterial pressure. A. Blood glucose. All diabetic animals 
showed higher blood glucose at the end of the experiment (8 weeks). B. Albuminuria, expressed in mg of 
albumin excreted in 24 hours. Note that all groups showed elevated levels of albuminuria compared with 
the control group. C. Plasma albumin, in g/dl. All diabetic animals showed low values of plasma albumin, 
in the nephrotic range. D. Plasma creatinine, in mg/dl. All diabetic animals showed high plasma creatinine 
values. E. Creatinine clearance. All groups showed similar creatinine clearance values. F. NGAL qPCR. G. 
KIM-1 qPCR. H. After eight weeks of treatment, all groups showed a significant increase in systolic pressure 
than the control group. I. Diastolic pressure showed the same pattern than systolic pressure. $p<0.05 
comparing between males and females of the same group. All groups with different letters have 
significant differences (p<0.05). Letter c represents significant differences with BPA group (p<0.05). The 
graph represents mean values ± SEM. One-way ANOVA or Kruskal-Wallis test was performed for the 
comparison between groups. A two-way ANOVA test was performed for the comparison between sexes. 
3.3. Histological, immunohistochemical, and Q-PCR studies. BPA and D groups display similar 
renal histological changes at both glomerular and tubular compartments, including collapsed 
glomeruli, tubular dilatation, sloughing off the tubuloepithelial cells, and hyaline casts in the 
tubules' lumen.  Diabetic mice treated with BPA showed similar histological alterations observed 
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in these groups. Of note, glomerular damage analyzed as collapsed corpuscles percentage 
showed a sexual dimorphism pattern in BPA and D+BPA groups being male mice significantly 


























Figure 3. Histological examination (PAS-Alcian blue staining). A. Control kidney. B. Mice BPA-treated 
showed altered renal corpuscles and dilated convoluted tubules. C. The kidney of the diabetic mice 
showed both Bowman’s capsules and convoluted tubules extremely dilated. D. D+BPA mice showed 
mesangial expansion, some corpuscles were destroyed (*), and the epithelium in some tubules was 
damaged (star) (X300). E. Histogram compares the corpuscular surface in each group observing 
statistically significant differences between females and males in both control and BPA-treated groups. F. 
Histogram represents the collapsed renal corpuscles percentage, showing a sexual dimorphism pattern in 
BPA and D+BPA groups. *p<0.05; **p<0.01 using one-way ANOVA or Kruskal-Wallis test for the 
comparison between groups. A two-way ANOVA test was performed for the comparison between sexes. 
$$p<0.01 comparing between males and females of the same group. 
Immunolabeling with WT-1, a specific marker of podocytes, demonstrated that podocytes cell 
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littermates (figure 4). Interestingly, D+BPA animals display a further decrease in this parameter 






















Figure 4. WT-1 immunostaining. A. Control kidney. B. Mice BPA-treated is showing a reduction in the 
podocytes number vs. control animal. C. Diabetic mice presented a higher podocyte number than BPA-
treated animals but lower than control. D. D+BPA mice had the lowest number of podocytes (X300). E. 
The histogram shows statistically significant differences between all experimental groups. All groups with 
different letters have significant differences (p<0.01). One-way ANOVA or Kruskal-Wallis test was 
performed for the comparison between groups. A two-way ANOVA test was performed for the 
comparison between sexes. 
Cell death, including apoptosis, as analyzed by CHOP immunohistochemistry and TUNEL assay, 
respectively, were significantly increased in all group studies in comparison to their control 
littermates. D group presented the highest optical density in CHOP immunostaining (figure 5). 






































































Figure 5. CHOP immunostaining. A. In the control group, the CHOP labeling was observed in the blood 
vessel endothelial cells. B. In BPA-treated kidneys, the immunolabeling was increased and appeared in 
the apical cytoplasm of the tubuloepithelial cells. C. Diabetic mice presented the highest immunoreaction 
to CHOP antibody. D. D+BPA mice presented elevated immunostaining but lower than in diabetic mice 
(X300). E. Histogram showing the optical density of CHOP immunostaining. All groups with different 
letters have significant differences (p<0.01). One-way ANOVA or Kruskal-Wallis test was performed for 


































































Figure 6. TUNEL assay. A. Kidneys from control the group presented a small number of apoptotic cells. B. 
BPA-treated mice presented a higher number of apoptotic cells than controls. C. In diabetic mice, kidneys 
from males had a high number of dead cells; however, the female mice were similar to the control group. 
D. D+BPA mice showed the highest number of apoptotic cells (X300). E. Histogram shows the gender 
differences in each group. $$$$ p<0.0001 females vs. males. All groups with different letters have 
significant differences (p<0.05). One-way ANOVA or Kruskal-Wallis test was performed for the comparison 
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To explore if there was a compensatory mitotic response to the observed increase in cell death, 
cell proliferation was analyzed by PCNA immunostaining. Both BPA and D groups develop a 
significant proliferative response, even higher in female mice than their male littermates (figure 
7). Interestingly, D+BPA group also showed PCNA-upregulation compared to their control 



























Figure 7. PCNA immunostaining. A. Control groups showed a low number of proliferating cells. B. Kidneys 
from BPA-treated mice presented a higher number of PCNA positive cells than control groups, especially 
females. C. Diabetic mice showed a number similar to control in males and higher in females. D. D+BPA 
mice presented a high number of proliferating cells without any difference between gender (X300). E. 
Histogram representing the gender differences in each group. All groups with different letters have 
significant differences (p<0.05). $p<0.05; $$$$p<0.0001 females vs. males.  One-way ANOVA or Kruskal-
Wallis test was performed for the comparison between groups. A two-way ANOVA test was performed 
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We then explored the potential role of oxidative stress as an inflammatory mediator by 
analyzing lipid peroxidation as 4-HNE staining (figure 8). Control and BPA animals showed a 
sexual dimorphism pattern being significantly higher in the male. All treated mice, except D+BPA 
























Figure 8. 4-HNE immunolabeling.  A. Control group. B. BPA-mice showed an important 4-HNE elevation, 
compared to their control group. Furthermore, BPA was the only treated group with sexual dimorphism 
pattern, similar than control. C. D group showed an important elevation without sexual dimorphism 
pattern. D. Only females D+BPA showed higher 4-HNE staining. E. Histogram represents the optical 
density of 4-HNE immunostaining. All groups with different letters have significant differences (p<0.01). 
One-way ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way 
ANOVA test was performed for the comparison between sexes. 
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We finally explored the potential role of several inflammatory mediators in the present 
experimental model (figures 9 and 10). No significant changes in the expression of TNF-α, MCP-
1, and IL-1β were observed in BPA-treated groups (figures 9A, B, C). The same expression pattern 
was observed in MCP-1 immunolabeling (figure 10). By contrast, all of them were significantly 
upregulated in D animal group. Moreover, D+BPA group showed a significant upregulation of 
MCP-1. Figure 9D showed a significant upregulation of IL-10 restricted to BPA animal group. TGF-
β and its receptor, a well-characterized system involved in both BPA and renal diabetic damage, 
were analyzed by Q-PCR. TGF-β was significantly upregulated in all animal groups, being 
significantly higher in the D+BPA group. The latter observation suggests that BPA might 
potentiate TGF-β upregulation in diabetic mice (figure 9E). Interestingly, the D+BPA group also 
displays the upregulation of the TGF-β receptor (figure 9F). No sexual dimorphisms were 
















Figure 9. Quantitative RT-PCR. A. TNF-α. The highest relative expression of the inflammatory messenger 
corresponds to the D group. B. MCP-1. As in the previous case, the highest relative expression of the 
inflammatory marker MCP-1 corresponds to the D group. C. IL-1β. The same expression pattern was 
observed as in the other two pro-inflammatory cytokines. D. IL-10. The expression of this anti-
inflammatory cytokine only increased in the BPA group E. TGF-β1. D+BPA group showed the highest 
relative expression of TGF-β1 mRNA. F.  TIIR. The only differences are observed between groups D and 
D+BPA. *p<0.05; **p<0.01 using the Kruskal-Wallis test for the comparison between groups. All groups 
with different letters have significant differences (p<0.05). Letter c represents significant differences with 
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Figure 10. MCP-1 immunolabeling. A. In control kidneys, MCP-1 was observed in the cytoplasm of some 
epithelial cells of the collecting tubules. B. In the BPA group, the labeling was similar to the control group. 
C. Diabetic mice showed a high number of labeled cells and higher intensity in the MCP-1 expression. D. 
Kidneys from D+BPA mice presented an elevated immunolabeling to MCP-1 antibody but with less 
intensity than diabetic animals (X300). E. Histogram represents the optical density of MCP-1 
immunostaining. All groups with different letters have significant differences (p<0.0001). One-way 
ANOVA or Kruskal-Wallis test was performed for the comparison between groups. A two-way ANOVA test 

































Experimental and human studies have demonstrated a significant association between urinary 
excretion of BPA and albuminuria, a well-known factor involved in the mechanism of renal 
disease progression [33,34,47,48]. In this regard, Hu et al. [47], in a prospective study of 302 
patients followed for six years, have demonstrated serum BPA as a predictor of chronic kidney 
disease in primary hypertension. Serum BPA was also described as a risk factor in the 
progression of diabetic nephropathy in patients with type 2 diabetes [48]. Our present study 
provides an experimental animal model to support these findings since we describe that the oral 
administration of BPA is capable of promoting in the kidney pathophysiological and molecular 
alterations that resemble early DN, such as increased in UAE, hypertension, podocytopenia, 
apoptosis, collapsed glomeruli as well as CHOP and TGF-β system upregulation. 
We presently used the STZ model, which is considered the ‘work horse’ for experimental studies 
in diabetic nephropathy [49,50]. Consistent with previous findings in this model, diabetic mice 
developed renal hypertrophy and an increase in UAE, hypertension, podocytopenia, apoptosis 
[39,51–55], and the upregulation of CHOP, PCNA, MCP-1, and TGF-β throughout this study 
[51,52]. 
Regarding BPA doses used in our study’s, animals received 150 µg/ml (21.2 mg/kg). Currently, it 
is accepted that the "no observed adverse effect level", known as NOAEL, in the renal system is 
50 mg/kg [56,57], which is at least twice times higher than the dose used. European Food Safety 
Authority (EFSA) currently uses this NOAEL dose to estimate the tolerable daily intake (TDI) of 4 
µg/kg in humans [57–59]. In the EFSA 2015 report, it is estimated that the total exposure to BPA 
in the population could reach almost half of the TDI (around 1.5 µg/kg) [57], which is consistent 
with using an equivalent concentration half of the NOAEL in animal models. 
BPA-treated mice did not display significant polyuria as expected from previous publish [37] and 
unpublished observations using BPA concentration higher than renal NOAEL. Therefore, polyuria 
and the risk of higher BPA exposure were restricted to D+BPA mice. In any case, the BPA group 
developed similar renal changes to those of the diabetic group. Although this represents a 
limitation in our studies, it emphasizes the role of BPA exposure and the importance of 
maintaining strict metabolic control of diabetic patients to avoid osmotic diuresis and BPA 
overexposure. 
One unexpected finding of this study was that all male mice from the D+BPA group died by the 
tenth week of the experimental procedure. Unfortunately, a limitation of the study is the lack of 
data beyond eight weeks. Therefore, albeit the cause of the death cannot be determined with 
certainty, we can only assume that it was related to hydroelectrolytic disturbances in animals 
with impaired renal function. 
In accordance with previous works [41–44], control male mice showed increased in body weight 
and renal hypertrophy compared to female littermates. Besides the observed sexual survival 
dimorphism pattern, other significant pathophysiological differences between male and female 
animals were found. Treated male animals display significant increases UAE, and renal damage 
analyzed as collapsed glomeruli. Renal cell proliferation, as analyzed by PCNA staining, was the 
only parameter found to be significantly higher in female animals than in the males' littermates.  
Although endogenous creatinine clearance showed no significant differences among animal 
groups studied, serum creatinine displayed a statistically significant increase in both D and 
D+BPA groups compared to their correspondent's controls. It is known that to a variable degree, 
tubules secrete creatinine, which, by itself, would lead to an overestimation of renal function 
[60]. To further investigate BPA effects at the molecular level on the kidney, the gene expression 
of the kidney damage biomarkers Havcr-1 and Lidocalpin-2, which codify KIM-1 and NGAL, 
respectively, were evaluated [45,46]. Both genes were significantly increased in all treated mice 
in comparison to their control littermates. Interestingly, NGAL also showed a significant further 
increase in diabetic animals receiving BPA. All renal functional data studied supported the notion 
that BPA exposures to mice induced kidney damage in control mice and exacerbated injury in 
diabetic mice. 
All treated male and female mice showed similar impairment of renal function. In contrast, male 
mice displayed a significant increase in urinary output restricted to D animal group, and female 
mice showed a significant increase in cell proliferation in this animal group. It is thus tempering 
to speculate, albeit not probed in the present setting, that increased urinary output could 
predispose to hydro electrolyte disturbances while increased in renal cell proliferation could, at 
least in theory, partially explain differences in sexual survival dimorphism pattern. On the other 
hand, D+BPA animal group did not display an additional effect on cell proliferation. 
Several studies have demonstrated that most renal cells grown in high glucose conditions 
initially present a self-limited proliferation, followed by cell cycle arrest in the G1-phase, 
undergoing cellular hypertrophy [51,61]. These cellular events require the combined effect of 
mitogen-induced entry into the cell cycle and subsequent arrest at the G1 modulated by cell 
cycle regulatory proteins, including TGF-β1. Therefore, it is possible to speculate that the intense 
hypertrophy response observed in the D+BPA group may abrogate the mitogenic effect induced 
by BPA. 
Sexual dimorphism could be due to different susceptibility to BPA, physiological differences, 
including sexual hormones, particularly androgen [62], or a combination of both. Indeed, 
different responses in males and females to the same exposure to BPA have been found. Most 
of the studies have been carried out mainly on the gestational or perinatal effect, where it has 
been determined that BPA can exert a different effect in males and females at the hepatic 
[23,24], adipogenic [25], neurological [26–28], endocrine [29], immunological [30], or renal level 
[31]. Furthermore, it has been observed that BPA is capable of inducing an agonist action on the 
estrogen receptor and an antagonist on the androgen receptor [63]. 
On the other hand, there is evidence that suggests that females have higher nephroprotection 
than males. In experimental animal models, female rats have increased protection against post-
ischemic renal failure [64], doxorubicin treatment [65], and cisplatin treatment [66]. 
Epidemiological studies in humans also suggest the existence of nephroprotection in women. In 
this sense, one of the most extensive studies carried out is that of Neugarten et al. [67], where 
after performing a meta-analysis with 68 different studies and a total of 11,345 patients, they 
determined that men with chronic kidney disease caused by various etiologies show a much 
faster decline in kidney function than women. In another epidemiological study with 27,805 
patients with type I diabetes, a statistically significant relationship was observed between the 
male sex and microalbuminuria development, an early marker of kidney disease [68]. 
Furthermore, probably because a BPA dose equivalent to half the NOAEL was used, the BPA 
group results do not show remarkable differences to the control group at the biometric and 
biochemical levels. However, an increase in albuminuria (less than in the diabetic groups, but 
equally significant) and a significant increase in blood pressure were observed. On the other 
hand, the histological studies showed interesting differences to the control group by showing 
the collapsed glomeruli, and a reduction in the number of cells, with the subsequent 
confirmation by TUNEL of the increase of apoptotic cells and a reduction in the number of 
podocytes labeled with WT-1.  
Regarding sexual dimorphism, were observed differences in the renal hypertrophy index and 
albuminuria, with males presenting a higher number in both parameters. Although podocyte 
(WT-1) immunostaining showed no sexual dimorphism, particularly in the D+BPA group, the 
number collapsing glomerulus did show sexual dimorphism. Thus, damaged glomeruli could 
account for the observed increase in the UAE in the male D+BPA group.   
 
 
In general, the results show that the route of administration of BPA and the dose used after 
eight weeks of treatment can exert an effect on the renal system similar to that described in the 
early stages of the development of diabetic nephropathy [69,70] at a dose lower than that 
considered "NOAEL" of the renal system [56].  
Although there are limitations when using mouse models for assessing renal failure or long-term 
histomorphological changes [71], our findings may have pathophysiological implications since 
the amount of proteinuria, podocyte number and the upregulation of kidney damage 
biomarkers are reliable predictors of the progression of renal disease [37,72–75]. Together with 
our present findings, all the available data strongly suggest that even low-grade proteinuria 
associated with BPA exposure might involve podocyte damage of an uncertain (or as yet 
unexplored) outcome, jointly with the biomarkers mentioned above are indicators of the need 
for future studies and raising a red flag of caution against increasing BPA exposure. Our data 
agree with Ruiz-Priego et al. [76], supporting the use of NGAL and KIM-1 as biomarkers of BPA-
nephropathy. 
Animals treated with BPA showed a significant increase in the expression of the CHOP protein. 
The kidney is one of the organs with the highest ER stress susceptibility because the fractional 
protein synthesis rates are almost half the total body load daily [77]. The possibility that ER stress 
is involved in the development of diabetic nephropathy has been described. Among the three 
signaling pathways that make up the ER stress response system, two of them are protective, and 
the remaining one, ERK-ATF4-CHOP, induces apoptosis in some kidney diseases [78]. It is 
interesting to note that both diabetic animals (as in other publications [79]) and those treated 
with BPA showed high CHOP levels. In this way, the hypothesis that BPA can induce similar 
damage to diabetic nephropathy is reaffirmed. 
In order to get inside into the molecular mechanisms involves in the renal changes observed, we 
first analyzed the proapoptotic and profibrogenic TGF-β system. As expected, diabetic and BPA 
groups display the upregulation of TGF-β, a cytokine involved in hypertrophy, apoptosis, and 
renal fibrosis. Interestingly, this upregulation was significantly higher in the D+BPA group, thus 
suggesting a molecular mechanism for the observed renal parameters impairment in the latter 
group. 
We then analyzed the renal expression of MCP-1, TNF-α and IL-1 well-known pro-inflammatory 
mediators in DN [80]. As expected, these molecules were found to be upregulated in D mice. On 
the contrary, BPA mice did not show changes in the expression of these pro-inflammatory 
mediators. It is well stablished that BPA can promote an inflammatory response by upregulating 
inflammatory mediators such as IL-1β, TNF-α, or MCP-1 [76,81,82], it is also known that it can 
also trigger the expression of anti-inflammatory molecules like IL-10 or TGF-β [83,84]. Herein we 
observed a significant upregulation of IL-10 restricted to BPA-treated mice. This finding could 
account, at least in part, for the lack of activation of proinflammatory mediators in this animal 
group.  
In any case, recent observations using a BPA concentration higher than renal NOAEL, 
demonstrate the upregulation of several proinflammatory mediators (including MCP-1, RANTES 
or IL-6) [76]. All data available strongly suggest that the level of BPA exposure might be critical 
to promote renal inflammation. 
In conclusion, we observed that oral administration of BPA is capable of promoting in the kidney 
alterations that resemble early DN, such as increased in kidney damage biomarkers NGAL and 
KIM-1, UAE, hypertension, podocytopenia, apoptosis, collapsed glomeruli as well as TGF-β, 
CHOP and PCNA upregulation, albeit they did not develop changes in serum creatinine as 
observed in D mice. Moreover, UAE, collapsed glomeruli, PCNA staining, TGF-β (TIIR), and animal 
survival, significantly impaired in diabetic animals receiving BPA. Furthermore, UAE, collapsed 
glomeruli and animal survival also displayed a sexual dimorphism pattern. 
Collectively, these data show that further translational studies are needed to clarify the potential 
role of BPA in renal diseases, particularly in diabetic patients.  
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Supplementary Table 1. SYBR Green primers and TaqMan probes. 
RT-PCR primers   
TNF-α Forward 5´- AGGCACTCCCCCAAAAGATG-3´ 
 Reverse 5´-TGAGGGTCTGGGCCATAGAA 
TGF-β1 Forward 5´-GCAACATGTGGAACTCTACCAG-3’ 
 Reverse 5´-CAGCCACTCAGGCGTATCA-3’ 
TIIR Forward     5′- CCTACTCTGTCTGTGGATGACCT - 3′  
 Reverse 5´- ACTTCCGGGGCCATGTAT - 3′ 
MCP-1 Forward  5’- CACTCACTCCACAACCCAAGA - 3’ 
 Reverse  5’- CAAAGACCCTCAAAACATCCC - 3’ 
IL-10 Forward  5′- AGGGTGTCTCCTTCCTCACA - 3’ 
 Reverse  5′- TGTTACACTCGCCCCCTTTG - 3’ 
IL-1β Forward  5′- TGGGCCTCAAAGGAAAGAAT - 3’ 
 Reverse  5′- CAGGCTTGTGCTCTGCTTGT - 3’ 
KIM-1 Forward  5′- ATGAATCAGATTCAAGTCTTC - 3’ 
 Reverse  5′- TCTGGTTTGTGAGTCCATGTG - 3’ 
NGAL Forward  5′- CACCACGGACTACAACCAGTTCGC - 3’ 
 Reverse  5′- TCAGTTGTCAATGCATTGGTCGGTG - 3’ 
TaqMan probes   
β-Actin Forward 5´- GCTCTGGCTCCTAGCACCAT- 3´ 
 Reverse 5´- GCCACCGATCCACACAGAGT- 3´ 
 Probe  5´- ATCAAGATCATTGCTCCTCCTGAGCGC- 3´ 
 
